Hippocampal volume, CSF biomarkers and cognition in Parkinson’s disease without dementia

Takeaway

  • Hippocampal volumes, specifically in Cornu Ammonis 1 (CA1) and hippocampal-amygdaloid transition areas (HATA), are predicted by cognitive status but not cerebrospinal fluid (CSF) amyloid-β 1-42 (Aβ42) in patients with non-demented Parkinson’s disease (PD).

Why this matters

  • Few studies have explored the association between hippocampal atrophy, CSF Aβ42 levels and cognitive deficit in PD despite all three being present in these patients, with abnormal CSF Aβ42 levels particularly seen in patients with PD and dementia.

  • Cognitive status in patients with PD may constitute a predictive marker for hippocampal atrophy, which may, in turn predict dementia risk, leading to potentially earlier intervention.